Oligonucleotide Synthesis Market is Projected to Reach USD 12.45 Billion by 2032

According to a new report published by Introspective Market Research, titled, Oligonucleotide Synthesis Market by Product (Synthesized Oligonucleotides, Reagents & Consumables, Equipment), Application (Research, Diagnostics, Therapeutics), and End-User (Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, Diagnostic Laboratories), The Global Oligonucleotide Synthesis Market Size Was Valued at USD 10.49 Billion in 2023 and is Projected to Reach USD 12.45 Billion by 2032, Growing at a CAGR of 16%. Oligonucleotide synthesis refers to the chemical production of short DNA or RNA molecules, known as oligonucleotides, with a specific sequence. These custom-made nucleic acid sequences are foundational tools in molecular biology, biotechnology, and medicine. The process involves sequentially adding nucleotide building blocks to a growing chain, allowing for the creation of precise genetic materials essential for various applications.

The market for oligonucleotide synthesis is rapidly expanding due to its critical role in numerous scientific advancements. Oligonucleotides serve as probes for gene expression analysis, primers for PCR amplification, gene editing tools (like CRISPR guides), and therapeutic agents, particularly in the development of antisense oligonucleotides (ASOs) and siRNA. Their bespoke nature and increasing utility across diagnostics, research, and drug discovery make them invaluable components in modern life sciences.
The burgeoning field of genomics and personalized medicine stands as a pivotal growth driver for the oligonucleotide synthesis market. As our understanding of genetic diseases expands, there is an increasing demand for custom oligonucleotides for targeted gene sequencing, mutation detection, and genetic screening. The rise of gene editing technologies like CRISPR, which rely heavily on guide RNAs, further amplifies this demand. These advancements are pushing the boundaries of therapeutic development and diagnostics, necessitating the high-throughput and precise synthesis of oligonucleotides to tailor treatments to individual genetic profiles.
A significant market opportunity lies in the therapeutic applications of oligonucleotides, particularly in the development of novel antisense oligonucleotides (ASOs) and small interfering RNAs (siRNAs). These therapeutic oligonucleotides hold immense promise for treating a wide array of diseases, including genetic disorders, cancer, and infectious diseases, by specifically modulating gene expression. Continued advancements in oligonucleotide chemistry, delivery systems, and clinical trials are paving the way for a new generation of RNA-based therapeutics. Companies investing in research and development within this therapeutic space, coupled with strategic collaborations, are poised to capture substantial market share.

Oligonucleotide Synthesis Market, Segmentation

Product

  • The Product segment is further classified into Synthesized Oligonucleotides, Reagents & Consumables, and Equipment. Among these, the Synthesized Oligonucleotides sub-segment accounted for the highest market share in 2023. This dominance is attributed to the direct demand from researchers, diagnostic laboratories, and pharmaceutical companies for custom-designed DNA and RNA sequences for their specific experimental and therapeutic needs. The increasing complexity and diversity of applications, from PCR primers to advanced therapeutic oligonucleotides, drive the continuous need for these ready-to-use, custom-synthesized products. This segment is fundamental to innovation across all areas of molecular biology and biotechnology.

Application

  • The Application segment is further classified into Research, Diagnostics, and Therapeutics. Among these, the Research sub-segment accounted for the highest market share in 2023. Oligonucleotides are fundamental tools in virtually every aspect of molecular biology research, including gene sequencing, PCR, cloning, gene expression studies, and functional genomics. Academic institutions, biotechnology firms, and pharmaceutical companies extensively utilize custom-synthesized oligonucleotides to explore gene function, validate drug targets, and develop new diagnostic assays. The continuous innovation in life sciences research directly fuels the demand for high-quality, custom oligonucleotides as essential experimental components.

Some of The Leading/Active Market Players Are-

  • Thermo Fisher Scientific Inc. (USA)
  • Merck KGaA (Germany)
  • Danaher Corporation (USA)
  • Twist Bioscience Corporation (USA)
  • Sartorius AG (Germany)
  • Agilent Technologies, Inc. (USA)
  • Eurofins Scientific SE (Luxembourg)
  • Integrated DNA Technologies (IDT) (USA)
  • Bio-Rad Laboratories, Inc. (USA)
  • LGC Biosearch Technologies (UK)
  • GenScript Biotech Corporation (China)
  • Arbor Biosciences (USA)
  • Atum (USA)
  • Axolabs GmbH (Germany)
  • Sigma-Aldrich (USA)
  • other active players.

Key Industry Developments

  • In September 2023, Twist Bioscience announced the expansion of its oligonucleotide synthesis capabilities with new high-throughput platforms, aiming to meet the growing demand for custom DNA and RNA for various applications. This expansion significantly boosts their capacity to deliver a broader range of complex oligonucleotide products. The investment underscores Twist Bioscience's commitment to advancing synthetic biology and supporting genomic research and therapeutic development with increased speed and scale.

  • In April 2023, Integrated DNA Technologies (IDT) launched new product offerings designed to optimize oligonucleotide synthesis and purification for enhanced specificity in challenging applications. These innovations focus on improving the quality and purity of custom oligonucleotides. The new offerings provide researchers with more reliable and efficient tools, particularly crucial for sensitive diagnostic assays and highly specific gene editing experiments, ensuring greater accuracy and reproducibility in their molecular biology workflows.

Key Findings of the Study

  • Synthesized oligonucleotides hold the largest market share due to widespread application.
  • Research applications dominate, driven by continuous scientific advancements.
  • The rise of genomics and personalized medicine is a major growth driver.
  • Therapeutic oligonucleotides (ASOs, siRNAs) represent a significant market opportunity.
  • Technological advancements in synthesis and purification are key market trends.

Share On :

Posted by  T Kumbhar

T. Kumbhar is a results-driven Senior Market Research Consultant at IMR, specializing in market trends, competitive intelligence, and data-driven insights. With extensive experience across Agrochemicals, Food Tech, Consumer Goods, Automotive, and Construction, he helps businesses make informed strategic decisions through in-depth research and analysis. His expertise includes market research, competitive analysis, business strategy, forecasting, pricing strategies, and consumer insights.